HC Wainwright Issues Positive Forecast for Inozyme Pharma (NASDAQ:INZY) Stock Price

Inozyme Pharma (NASDAQ:INZY) had its price target increased by research analysts at HC Wainwright from $14.00 to $16.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Other equities analysts have also recently issued reports about the company. Needham & Company LLC restated a “buy” rating and set a $23.00 target price on shares of Inozyme Pharma in a report on Wednesday, November 6th. Raymond James assumed coverage on shares of Inozyme Pharma in a research note on Thursday, December 12th. They issued an “outperform” rating and a $26.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and set a $12.00 target price (down from $15.00) on shares of Inozyme Pharma in a research note on Tuesday, November 5th. Finally, Stifel Nicolaus assumed coverage on shares of Inozyme Pharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $16.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $17.25.

Inozyme Pharma Trading Down 25.0 %

Shares of Inozyme Pharma stock traded down $0.70 on Friday, reaching $2.10. The company had a trading volume of 1,405,871 shares, compared to its average volume of 676,506. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. The firm has a market cap of $134.90 million, a PE ratio of -1.35 and a beta of 1.35. The firm’s 50 day moving average price is $3.07 and its two-hundred day moving average price is $4.40. Inozyme Pharma has a 52-week low of $2.00 and a 52-week high of $7.80.

Inozyme Pharma (NASDAQ:INZY) last announced its earnings results on Tuesday, November 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.05. Sell-side analysts predict that Inozyme Pharma will post -1.59 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Eventide Asset Management LLC increased its position in shares of Inozyme Pharma by 5.0% in the 3rd quarter. Eventide Asset Management LLC now owns 4,134,436 shares of the company’s stock valued at $21,623,000 after purchasing an additional 198,216 shares during the last quarter. Samlyn Capital LLC grew its stake in shares of Inozyme Pharma by 15.0% during the second quarter. Samlyn Capital LLC now owns 3,350,535 shares of the company’s stock worth $14,943,000 after purchasing an additional 437,622 shares in the last quarter. Affinity Asset Advisors LLC grew its stake in shares of Inozyme Pharma by 8.1% during the second quarter. Affinity Asset Advisors LLC now owns 2,856,252 shares of the company’s stock worth $12,739,000 after purchasing an additional 213,733 shares in the last quarter. Millennium Management LLC increased its holdings in Inozyme Pharma by 154.1% in the second quarter. Millennium Management LLC now owns 1,787,947 shares of the company’s stock valued at $7,974,000 after buying an additional 1,084,341 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Inozyme Pharma by 1.7% in the third quarter. Geode Capital Management LLC now owns 1,171,172 shares of the company’s stock valued at $6,126,000 after buying an additional 19,499 shares in the last quarter. Hedge funds and other institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.